Stockscreener 앱 받기
24.23
2.67%
0.63
시간 외 거래:
23.32
-0.91
-3.76%
전일 마감가:
$23.60
열려 있는:
$23.96
하루 거래량:
522.23K
Relative Volume:
0.71
시가총액:
$1.80B
수익:
$105.97M
순이익/손실:
$-81.13M
주가수익비율:
-22.45
EPS:
-1.0791
순현금흐름:
$-35.43M
1주 성능:
+3.33%
1개월 성능:
+0.46%
6개월 성능:
+49.94%
1년 성능:
+89.30%
1일 변동 폭
$23.96
$24.82
1주일 범위
$23.08
$24.82
52주 변동 폭
$9.03
$28.49
Zymeworks Inc. Stock (ZYME) Company Profile
명칭
Zymeworks Inc.
전화
604-678-1388
주소
1385 West 8th Avenue, Suite 540, Vancouver, BC
Compare ZYME vs VRTX, REGN, ALNY, ARGX, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ZYME
Zymeworks Inc.
|
24.23 | 1.75B | 105.97M | -81.13M | -35.43M | -1.0791 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-12 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2025-12-03 | 개시 | Citizens JMP | Mkt Outperform |
| 2025-10-24 | 재개 | Wells Fargo | Equal Weight |
| 2025-10-14 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-10-10 | 개시 | B. Riley Securities | Buy |
| 2025-05-20 | 개시 | TD Cowen | Buy |
| 2024-12-16 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-11-07 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-11-01 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-03-21 | 재개 | Wells Fargo | Overweight |
| 2023-01-04 | 재확인 | H.C. Wainwright | Neutral |
| 2022-12-20 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-11-01 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-10-21 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-10-04 | 재개 | Wells Fargo | Overweight |
| 2022-05-05 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-03-15 | 개시 | Evercore ISI | Outperform |
| 2021-12-10 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-17 | 재개 | Guggenheim | Neutral |
| 2021-10-07 | 개시 | Jefferies | Hold |
| 2021-03-31 | 개시 | Credit Suisse | Outperform |
| 2021-02-25 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-08 | 재개 | H.C. Wainwright | Buy |
| 2021-01-25 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-09-29 | 재개 | JP Morgan | Neutral |
| 2020-08-06 | 개시 | SVB Leerink | Outperform |
| 2020-01-10 | 개시 | Wolfe Research | Outperform |
| 2019-12-09 | 개시 | JP Morgan | Neutral |
| 2019-11-25 | 개시 | H.C. Wainwright | Buy |
| 2019-11-20 | 개시 | Guggenheim | Buy |
| 2019-09-30 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2019-08-30 | 개시 | Stifel | Buy |
| 2019-07-18 | 개시 | Deutsche Bank | Buy |
| 2018-05-11 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2018-03-19 | 개시 | Raymond James | Outperform |
모두보기
Zymeworks Inc. 주식(ZYME)의 최신 뉴스
Tranche Update on Zymeworks Inc.'s Equity Buyback Plan announced on November 18, 2025. - marketscreener.com
Zymeworks Inc stock faces renewed scrutiny amid biotech sector volatility and pipeline updates - AD HOC NEWS
Aug Weekly: Does Zymeworks Inc stock have upside surprise potentialGap Up & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Zymeworks to Highlight Pipeline and Asset Strategy at Key Investor Conferences - TipRanks
Zymeworks Announces Participation in Upcoming Investor Conferences - The Manila Times
Zymeworks executives head to two April healthcare investor events - Stock Titan
Published on: 2026-03-23 15:16:44 - baoquankhu1.vn
Zymeworks Inc. (ZYME) reports Q4 loss, lags revenue estimates - MSN
Zymeworks Inc stock faces biotech volatility amid pipeline updates and market shifts - AD HOC NEWS
Will Zymeworks Inc benefit from rising consumer demand2026 WrapUp & Weekly Market Pulse Updates - baoquankhu1.vn
Zymeworks Highlights New Ziihera Data to Broaden HER2 Cancer Reach - TipRanks
Experimental breast cancer drug shrinks tumors in 6 weeks at AACR 2026 - Stock Titan
Does Zymeworks (ZYME) Pan-RAS ADC Push Reveal a Durable Edge in Targeted Oncology? - Sahm
Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting - Koreabizwire
Zymeworks to present clinical data on cancer drug candidate at AACR - Investing.com Australia
Zymeworks to present clinical data on cancer drug candidate at AACR By Investing.com - Investing.com South Africa
Zymeworks Highlights ADC and Novel Pan-RAS Platform Data Ahead of AACR Meeting - TipRanks
Zymeworks to Present Clinical and Preclinical Data on ADC - GlobeNewswire
New cancer drug conjugates aim at tough RAS tumors in Zymeworks data - Stock Titan
A Look At Zymeworks (ZYME) Valuation After New AACR 2026 Antibody Drug Conjugate Pipeline Data - Sahm
Wall Street Analysts See a 76.74% Upside in Zymeworks (ZYME): Can the Stock Really Move This High? - MSN
Prosight Management LP Cuts Stake in Zymeworks Inc. $ZYME - MarketBeat
Value Recap: Does Zymeworks Inc have strong EBITDA marginsTrade Analysis Report & Accurate Buy Signal Notifications - baoquankhu1.vn
Zymeworks (NASDAQ:ZYME) Trading Up 9.7%What's Next? - MarketBeat
Assessing Zymeworks (ZYME) Valuation After Q4 Updates And Improved Clinical And Funding Outlook - Sahm
Zymeworks (ZYME) Price Target Raised to $48 by Evercore ISI Grou - GuruFocus
Will Zymeworks' (ZYME) Wider Losses and ESOP Shelf Offering Recast Its Long-Term Equity Story? - Sahm
Zymeworks (NASDAQ:ZYME) Price Target Raised to $46.00 - MarketBeat
Zymeworks (ZYME) Rating Maintained, Price Target Raised to $46 b - GuruFocus
Q1 Earnings Forecast for Zymeworks Issued By Lifesci Capital - MarketBeat
Zymeworks FY25 Review: From Milestone Volatility To 2026 Upside (NASDAQ:ZYME) - Seeking Alpha
Zymeworks Inc. (NASDAQ:ZYME) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Zymeworks (NASDAQ:ZYME) Trading 2.8% Higher on Analyst Upgrade - MarketBeat
Forecasting The Future: 4 Analyst Projections For Zymeworks - Benzinga
Zymeworks (ZYME) Target Price Raised by Leerink Partners to $58 - GuruFocus
Stifel raises Zymeworks stock price target on royalty deal value By Investing.com - Investing.com Canada
Stifel raises Zymeworks stock price target on royalty deal value - Investing.com
Zymeworks Inc. (NASDAQ:ZYME) Q4 2025 Earnings Call Transcript - Insider Monkey
Citizens reiterates Zymeworks stock rating on strong cash position - Investing.com Nigeria
Citizens reiterates Zymeworks stock rating on strong cash position By Investing.com - Investing.com Australia
Zymeworks Inc (ZYME) Q4 2025 Earnings Call Highlights: Strategic Milestones and Financial Resilience By GuruFocus - Investing.com Canada
Decoding Zymeworks Inc (ZYME): A Strategic SWOT Insight - GuruFocus
Zymeworks secures $250M royalty financing from Royalty Pharma - Investing.com South Africa
Zymeworks (ZYME) Advances with Promising Zanidatamab Results - GuruFocus
Jefferies reiterates Zymeworks stock rating on financing deal By Investing.com - Investing.com Canada
Jefferies reiterates Zymeworks stock rating on financing deal - Investing.com South Africa
Zymeworks (ZYME) Reveals Q4 Revenue Drop and Strategic Focus Shi - GuruFocus
Zymeworks Inc (ZYME) Q4 2025 Earnings Call Highlights: Strategic Milestones and Financial Resilience - GuruFocus
Zymeworks Secures $250 Million Non-Dilutive Royalty-Backed Financing from Royalty Pharma for Ziihera Royalties - Minichart
Zymeworks Inc. (ZYME) Posts Fourth Quarter Loss, Falls Short of Revenue Projections - Bitget
Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing - citybiz
Zymeworks Inc. (ZYME) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.82%
자본화:
|
볼륨(24시간):